With 0.16 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.33 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $11.325 whereas the lowest price it dropped to was $10.41. The 52-week range on UPB shows that it touched its highest point at $29.46 and its lowest point at $10.36 during that stretch. It currently has a 1-year price target of $52.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of UPB was down-trending over the past week, with a drop of -19.71%, but this was down by -42.14% over a month.
Float and Shares Shorts:
At present, 53.60 million UPB shares are outstanding with a float of 15.86 million shares on hand for trading. On 2024-12-31, short shares totaled 2.3 million, which was 430.0 higher than short shares on 1732838400. In addition to Mr. Aaron Deykin M.D. as the firm’s Chief Medical Officer and Head of Research & Development, Dr. E. Rand Sutherland M.D., M.P.H., MPH serves as its CEO & Director.
Institutional Ownership:
Through their ownership of 0.64074 of UPB’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, UPB reported revenue of $607000.0 and operating income of -$18893000.0. The EBITDA in the recently reported quarter was -$18879000.0 and diluted EPS was -$0.409667.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With UPB analysts setting a high price target of 75.0 and a low target of 38.0, the average target price over the next 12 months is 56.5. Based on these targets, UPB could surge 581.82% to reach the target high and rise by 245.45% to reach the target low. Reaching the average price target will result in a growth of 413.64% from current levels.
Based on analyst estimates, the high estimate for the next quarter is -$0.4 and the low estimate is -$0.59. The average estimate for the next quarter is thus -$0.49.
